Clinical Research Directory

Inclusion Criteria: * \- Patient has provided written informed consent before participating in the trial. * Women aged ≥18 years. * Patient with documented diagnosis of stage II/III triple negative breast cancer (TNBC) as per ESMO guidelines. * Patient with Eastern Cooperative Oncology Group (ECOG) performance status ≤2. * Patient has adequate bone marrow function. * Patient has adequate renal function. * Patient has adequate liver function. * Patient has adequate heart function, i.e., no signs of heart failure or clinically significant arrhythmia. * Patient has completed the FACIT-Fatigue and FACT-G questionnaires at baseline. * Patient has access to a smart phone with access to the internet. * Patient with a weighing scale to measure weight. * Patient is able and willing to complete the trial, including the assigned questionnaires. * Patient can read and write in French. * Patient is covered by the French social security insurance or a similar healthcare insurance. Exclusion Criteria: * Persons referred to in Articles L1121-5 to L1121-8 of the Public Health Code (covering all protected persons: pregnant women, women in labour, breastfeeding mothers, persons deprived of their liberty by judicial or administrative order, minors, and persons subject to a legal protection measure: guardianship or curatorship). * Patient with prior breast cancer (invasive or non-invasive breast cancer). * Patient with a history of cancer within the last 5 years, except for basal cell carcinoma of the skin or pre-invasive carcinoma of the cervix. * Patient diagnosed with type I or II diabetes and treated. * Patient with a body mass index (BMI) \<18.5 kg/m² or patients with a BMI between 18.5 kg/m² and 20 kg/m² and weight loss ≥5% in the last 3 months or if a BMI \>20 kg/m² and weight loss \>10% in last 3 months. * Patient with food allergies. * Patient with metabolic disorders affecting gluconeogenesis or adaptation to short periods of fasting. * Patient already treated with a chronic immunosuppressive drug (dexamethasone used according to SOC is permitted) \>10 mg per day of prednisone or equivalent at study entry. * Previous episodes of symptomatic hypotension leading to loss of consciousness. * Previous episodes of symptomatic hypoglycemia. * Patient with behavioral eating disorders. * Patient already following a fasting or fasting mimicking diet. * Use of herbal preparations or medications interfering with chemoimmunotherapy pharmacokinetics: St. John's wort, kava, ephedra (ma huang), gingko biloba, aloe vera (and its derivatives), artemisinin (and its derivatives), and dehydroepiandrosterone (DHEA). * Use of vitamins or food supplements exceeding one-tenth (1/10) of the daily recommended dose except for vitamin D or containing calories. * Use of any supplement or product with unknown chemical composition. * Use of pharmacological agents known to interfere with fatigue assessment … * Use of nutraceutical agents known to interfere with fatigue assessment … * Agents interfering with FMD and metabolic pathways … * Patient with medical or psychological condition, in the opinion of the investigator, preventing her from determining the study or giving meaningful informed consent. * Patient participating in another interventional trial within 30 days prior to randomization.